Abstract
Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
